Abstract-Inactivation of dynorphin-(1 -8) in three in vitro isolated preparations, guinea-pig ileum, mouse vas deferens and rabbit vas deferens, was estimated by employing the relatively specific inhibitors of enkephalin-hydrolyzing enzymes. All three enzyme inhibitors, amastatin, captopril and phosphoramidon, significantly enhanced the inhibitory potency of dynorphin-(1 -8) in the three isolated pre parations.
Abstract-Inactivation of dynorphin-(1 -8) in three in vitro isolated preparations, guinea-pig ileum, mouse vas deferens and rabbit vas deferens, was estimated by employing the relatively specific inhibitors of enkephalin-hydrolyzing enzymes. All three enzyme inhibitors, amastatin, captopril and phosphoramidon, significantly enhanced the inhibitory potency of dynorphin-(1 -8) in the three isolated pre parations.
The magnitude of the enhancement of the dynorphin potency by captopril was significantly higher than that by either amastatin or phosphoramidon in guinea-pig ileum; that by amastatin was significantly higher than that by either captopril or phosphoramidon in rabbit vas deferens; and that by amastatin was similar to that by captopril, but significantly higher than that by phosphoramidon in mouse vas deferens.
The Ke values of three antagonists, naloxone, Mr 2266 and ICI 154129, against dynorphin-(1 -8) in the presence of the three peptidase inhibitors indicated that dynorphin-(1 -8) acted on kappa receptors in guinea-pig ileum and on both kappa and delta receptors in mouse vas deferens.
Since amastatin, captopril and phosphoramidon produced the naloxone-reversible inhibition of contractions of guinea-pig ileum in the presence of dynorphin-(1 -8), all three dynorphin-inactivating enzymes were indicated to be located very close to kappa receptors.
Enkephalins have been shown to be in activated by three enzymes, amastatin-sensi tive aminopeptidase, captopril-sensitive pep tidyl dipeptidase A (angiotensin I converting enzyme, kininase II, peptidyldipeptide hydro lase; EC 3.4.15.1) and phosphoramidon sensitive endopeptidase-24.11 ("enkepha linase", EC 3.4.24.11 ), in three in vitro isolated preparations, guinea-pig ileum (1), mouse vas deferens (2) and rat vas deferens (3). Since these enkephalin-hydrolyzing enzymes are located very close to opioid receptors (1-3), these enzymes are suggested not only to inactive the exogenously given enkephalin in the vicinity of opioid receptors but also suggested to play important roles in the termi nation of the action on opioid receptors of the enkephalin released from presynaptic nerve terminals.
Additionally, enkephalin has been demon strated to be almost exclusively hydrolyzed by these three enzymes, since enkephalin remains intact almost totally after it is in cubated with ileal or striatal membrane pre parations of guinea-pig for 60 min at 37'C in the presence of the inhibitors against these three enzymes, although enkephalin is com pletely hydrolyzed and free tyrosine and the Tyr-Gly-Gly fragment are produced when the incubation mixture does not contain the peptidase inhibitor (4).
Dynorphin-(1 -8), another endogenous opioid peptide, has been suggested to be also inactivated by peptidases in isolated pre parations such as rabbit vas deferens since its inhibitory action on the electrically-evoked contractions of the isolated preparation has been shown to be significantly enhanced by the pretreatment of the preparation with the mixture of peptidase inhibitors (5, 6). The enzyme involved in the inactivation of dynor phin-(1 -8), however, is unknown at present. In the present investigation, therefore, it was examined whether or not dynorphin-(1 -8) was inactivated by three enkephalin-hy drolyzing enzymes in three isolated prepara tions guinea-pig ileum, mouse vas deferens and rabbit vas deferens. Additionally, the preference of the opioid receptor type by dynorphin-(1 -8) was re examined in isolated preparations in the presence of peptidase inhibitors by employing the three opioid antagonists, since dynorphin (1 -8) had been reported to act on either kappa receptors in the preliminary experiments (7) or a different opioid-receptor type than the three classical opioid-receptor types, mu, kappa and delta type (8), and dynorphin (1 -9) had been indicated to act on both kappa and delta receptors (9) .
Moreover, it was estimated in the present investigation whether or not dynorphin inactivating enzymes were located very close to kappa receptors in guinea-pig ileum, since enkephalin-inactivating enzymes had been indicated to be located very close to mu re ceptors in guinea-pig ileum in the previous investigation (1).
Materials and Methods

Chemicals:
Gifts of compounds which were gratefully received were dynorphin In vitro isolated preparations: Male ICR JCL mice weighing 30-50 g, male Hartley guinea-pigs weighing 300-600 g, and male Japanese White rabbits weighing 2.5-3.5 kg were used for this study. The vasa deferentia from mice or rabbits, and the myenteric plexus-longitudinal muscle strip of guinea pig ileum were prepared and set up for elec trical stimulation as described previously (10, 11 ) . The % inhibition of electrically-evoked muscle contrations produced by an opioid peptide was plotted against the log concen tration of the peptide to estimate the IC50 (concentration of the opioid peptide to pro duce 50% inhibition of contractions). Amas tatin, captopril or phosphoramidon at the final concentration of 1 pM each was em ployed as an inhibitor of each peptidase in the present investigation since the previous studies had shown that the enkephalin hydrolyzing aminopeptidase, peptidyl dipep tidase A and endopeptidase-24. 11 were inhi bited almost completely with 1 /tM of amas tatin, 1 /iM of captopril, and 1 pM of phos phoramidon, respectively (1-4). Either a pep tidase inhibitor or the mixture of two or three peptidase inhibitors was given 10 min before the opioid administration.
The ratio of the potency and the % difference, shown in the tables, were calculated from the following fomulas: ratio of potency=1C50 before ad ditional treatment/IC50 after additional treat ment and % difference= [(IC50 before ad ditional treatment-IC50 after additional treat ment)/IC50 before additional treatment] x 100. The statistical significance of % dif ferences between IC50 values of two adjacent groups shown in the tables was determined by the paired Student's t-test. The KQ (equi librium dissociation constant) values of opioid antagonists against dynorphin-(1-8) were determined by the 'single' dose method (12) .
Results
Enhancing effects of peptidase inhibitors on the potency of dynorphin-(1-8): Dynor phin-(1 -8) dose-dependently inhibited the electrically-evoked contractions of all isolated preparations employed in the present in vestigation. Its IC50 value in guinea-pig ileum, mouse vas deferens and rabbit vas deferens was significantly decreased by the pretreatment of the preparation with mixture of three peptidase inhibitors, amastatin, cap topril and phosphoramidon, at the final con centration of 1 ,uM each at 10 min before the dynorphin administration (Table 1 ). Each peptidase inhibitor was then administered individually in the following experiments in order to determine which peptidase inhibitor had an enhancing effect on the inhibitory potency of dynorphin-(1 -8).
the effect of a particular peptidase inhibitor on the inhibitory potency of dynorphin was ex amined, therefore, the IC50 values of dynor phin before and after the addition of a par ticular peptidase inhibitor were estimated in the same preparation.
All three peptidase inhibitors significantly enhanced the inhibitory potency of dynor phin-(1 -8) in either guinea-pig ileum (Table  2) , mouse vas deferens (Table 3) or rabbit vas deferens (Table 4) . Table 1 . Enhancing effects of peptidase inhibitors on the inhibitory potency of dynorphin-(1 -8) in isolated preparations Table 2 . The enhancing effects of peptidase inhibitors on the inhibitory potency of dynorphin-(1-8) in guinea-pig ileum Table 3 . The enhancing effects of peptidase inhibitors on the inhibitory potency of dynorphin-(1 -8) in mouse vas deferens
In guinea-pig ileum, the magnitude of the enhancement of the dynorphin potency by amastatin was significantly higher than that by phosphoramidon, but significantly lower than that by captopril (Table 2) . Compounds were given to the bath at the dot. DYN, 5 nM of dynorphin-(1-8).
A, 1 I_tM of amastatin. C, 1 fiM of captopril. P , 1 1_,M of phosphoramidon. Nal, 1 IW of naloxone.
The degree of the augmentation of the dynorphin potency by amastatin was similar to that by captopril, but significantly higher than that by phosphoramidon in mouse vas deferens (Table 3) .
In rabbit vas deferens, the magnitude of the enhancement of the dynorphin potency by amastatin was significantly higher than that by captopril, and that by captopril was signifi cantly higher than that by phosphoramidon (Table 4) .
The inhibitory action of the peptidase inhi bitor on contractions of guinea-pig ileum in the presence of dynorphin-(1 -8): Either amastatin, captopril or phosphoramidon inhi bited the electrically-evoked contractions of guinea-pig ileum in the presence of dynor phin-(1-8) (Fig. 1) , although these pep tidase inhibitors by themselves did not de press the contractions in the absence of an opioid peptide (figures were not shown). The magnitude of the inhibition by each peptidase inhibitor, although it was slightly altered by changing the administration order of the pep tidase inhibitor, was the highest by captopril, the lowest by phosphoramidon and inter mediate by amastatin (Fig. 1 ) . The inhibition induced by peptidase inhibitors in the pre sence of dynorphin-(1 -8) was antagonized by naloxone (Fig. 1) . The degree of the antagonism by naloxone was not complete in some preparations as shown in Fig. 1 , but complete in other preparations. The apparent incomplete antagonism by naloxone was likely to be produced by the agonistic action of relatively high doses of naloxone on some preparations since dynorphin-(1 -8) at doses below 5 x 10-9 M in the presence of the three peptidase inhibitors did not inhibit the con tractions at all in all preparations after the ad ministration of relatively high doses (e.g ., 10-6 M) of naloxone which produced the slight inhibition of contractions by itself in some preparations.
The Ke values of opioid antagonists against dynorhin-(1 -8) in the presence of peptidase:
The Ke values against dynorphin-(1 -8) of naloxone, which had been shown to have a high affinity to mu receptors (13), were relatively high, while those of Mr 2266, which had been reported to have a high affinity to both mu and kappa receptors (13), were relatively low in guinea-pig ileum (Table 5) . Additionally, the Ke values of ICI 154129 , which had been found to have a relatively high affinity to delta receptors, a low affinity to mu receptors, and a very low affinity to kappa receptors (13), were very high in 3 among 6 preparations and they were not able to be estimated in the remaining 3 prepara tions of guinea-pig ileum because of no antagonism by ICI 154129 (Table 5) .
In mouse vas deferens, the Ke values against dynorphin-(1 -8) of naloxone, Mr 2266 and ICI 154129 were relatively high, relatively low and relatively low, respectively (Table 5 ). The fact that the magnitude of the enhance ment of the dynorphin potency by captopril was significantly higher than that by either amastatin or phosphoramidon in guinea-pig ileum suggests that captopril-sensitive pep tidyl dipeptidase A plays the most important role in the inactivation of dynorphin-(1 -8) in guinea-pig ileum. However, the important role of amastatin-sensitive aminopeptidase as well as captopril-sensitive enzyme in the inactivation of dynorphin-(1 -8) in mouse vas deferens is suggested by the finding that the degree of the enhancement of the dynor phin potency by amastatin was similar to that by captopril but significantly higher than that by phosphoramidon in mouse vas deferens. In rabbit vas deferens, amastatin-sensitive aminopeptidase is likely to play the most im portant role in the inactivation of dynorphin (1 -8) since the magnitude of the augmen tation of the dynorphin potency by amastatin has been shown to be significantly higher than that by either captopril or phosphor amidon. The minor role of phosphoramidon sensitive endopeptidase-24.1 1 in the inac tivation of dynorphin-(1 -8) in all three pre parations is indicated by the observation that the magnitude of the enhancement of the dynorphin potency by phosphoramidon was lower than that by either amastatin or cap topril in the three preparations.
The data in the present investigation along with those obtained previously (14, 15) amastatin is similar to that by captopril but higher than that by phosphoramidon in mouse vas deferens (15) . The reports that naloxone has a high af finity to mu receptors (Ke values ranging from 1 to 5 nM) and relatively low affinity to both kappa and delta receptors (Ke values ranging from 10 to 50 nM) (10, 13, 16, 17) ; Mr 2266 has a high affinity to both mu and kappa re ceptors (Ke values ranging from 1 to 5 nM) and relatively low affinity to delta receptors (Ke values ranging from 10 to 50 nM) (10, 13, 17) ; and ICI 154129 has a relatively high affinity to delta receptors (Ke values renging from 0.1 to 0.9 /iM), the lowest affinity to kappa receptors (Ke values being more than 20 /W) and intermediate affinity to mu re receptors (Ke values ranging from 7 to 8 tiM) (13, 18, 19) indicate that dynorphin-(1 -8) acts on kappa receptors in guinea-pig ileum and on both kappa and delta receptors in mouse vas deferens.
The fact that the relative importance of the three enzymes in the inactivation of dynorphin-(1 -8) is different from that of enkephalins may be caused by the fact that one opioid peptide is hydrolyzed more easily than the other by a particular enzyme as shown by the previous reports (14) , although the probability that the relative activity of three enzymes in the vicinity of mu receptors is different from that of kappa receptors can not be neglected since both [Met5] and [Leu5] enkephalin have been shown to act on mu receptors in guinea-pig ileum and on delta receptors in mouse vas deferens (13, 16), while dynorphin-(1 -8) has been suggested to act on kappa receptors in guinea-pig ileum and on both kappa and delta receptors in mouse vas deferens in the present investiga tion.
The preliminary experiment by employing crude enzyme preparations obtained from membrane fractions of guinea-pig ileum and striatum has shown that dynorphin-(1-8) is hydrolyzed by amastatin-sensitive amino peptidase at the Tyr-Gly bond, by phosphor amidon-sensitive endopeptidase-24.1 1 at the Gly-Phe bond, and captopril-sensitive peptidyl dipeptidase A at both Arg-Arg and Phe-Leu bonds (Hiranuma, T. and Oka, T., unpublished observation). Since [Leu5] enkephalin-Arg6, an initial hydrolysis product of dynorphin-(1 -8) by the captopril-sensitive enzymes, still has essentially the same potency as dynorphin-(1 -8) in mouse vas deferens (5), the observation that captopril has signifi cantly enhanced the potency of dynorphin (1 -8) in mouse vas deferens indicates that [Leu5]-enkephalin-Arg6 is further hydrolyzed by captopril-sensitive peptidase to Tyr-Gly Gly-Phe which is reported to have, if any, very weak potency on opioid receptors (20) .
All three enkephalin-hydrolyzing enzymes have been suggested to be very closely located to mu receptors in the guinea-pig ileum (1) and to delta receptors in mouse vas deferens (2) by employing enkephalin which has been indicated to act on mu receptors in guinea-pig ileum (13, 16) and delta receptors in mouse vas deferens (13, 16) . In the present investigation, these three enzymes were in dicated to very closely located to kappa re ceptors in guinea-pig ileum by employing dynorphin-(1 -8), which has been suggested to act on kappa receptors in guinea-pig ileum in the present study, since these enzymes have been shown to produce a significant con centration difference of dynorphin-(1-8) be tween the surrounding organ bath and the vicinity of kappa receptors as demonstrated in Fig. 1 , and such concentration difference can be produced only when these inac tivating-enzymes are located very closely to kappa receptors. The previous (1-3) and present investigation, therefore, strongly sug gest that there are three opioid-peptide-inac tivating enzymes in the vicinity of three types of opioid receptors, mu, kappa and delta receptors, as well as an unidentified type of opioid receptor in rat vas deferens.
